Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Thursday, 12 June 2014
AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma Phase IIa clinical study to commence in patients with severe asthma
Wednesday, 14 May 2014
MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Monday, 3 February 2014
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance AstraZeneca today announced that it has completed, on 1 February 2014, its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar